文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Mavacamten治疗梗阻性肥厚型心肌病的长期疗效与安全性

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.
PubMed 文献 · Eur Heart J · 2024-01-01

MAVA-LTE是一项为期5年的开放标签延伸研究,纳入231例来自EXPLORER-HCM的梗阻性肥厚型心肌病患者,评估Mavacamten长期疗效与安全性。至第180周,左室流出道压差、NT-proBNP及生活质量持续改善,LVEF从基线73.9%降至63.9%,8.7%患者出现LVEF短暂降至<50%但均恢复,未见新安全信号。

要点

  • Mavacamten长期治疗持续降低梗阻性HCM患者左室流出道压差并改善症状。
  • 长期随访中LVEF短暂降至<50%的发生率为8.7%,均经暂停治疗恢复。
  • 至第180周77.9%患者NYHA心功能分级至少改善一级。

核心结论

  • 长期Mavacamten治疗使梗阻性HCM患者心功能与症状持续改善,未发现新的安全性问题。
  • 长期随访中少数患者出现短暂、可逆的LVEF下降。

研究设计与样本

  • MAVA-LTE(NCT03723655)为正在进行的5年开放标签延伸研究,纳入完成EXPLORER-HCM(NCT03470545)的231例梗阻性HCM患者。
  • 截至最新数据截止,231例中211例(91.3%)仍在接受Mavacamten治疗。
  • 中位(范围)研究时间为166.1(6.0-228.1)周;185例(80.1%)完成第156周访视,99例(42.9%)完成第180周访视。

主要发现

  • 从基线至第180周,静息左室流出道压差平均(标准差)降低40.3(32.7)mmHg,Valsalva激发后降低55.3(33.7)mmHg。
  • NT-proBNP中位(四分位距)降低562(1162.5, 209)ng/L;EQ-5D-5L评分平均(标准差)改善0.09(0.17)。
  • 平均LVEF从基线73.9%降至第24周66.6%,第180周63.9%。
  • 第180周时,95例患者中74例(77.9%)NYHA心功能分级较基线至少改善一级。
  • 共739患者年暴露中,20例(8.7%;暴露调整发生率2.77/100患者年)发生22次LVEF短暂降至<50%并导致暂时中断治疗,所有患者LVEF均恢复至≥50%。

临床怎么用

  • 长期使用Mavacamten需监测LVEF,出现LVEF<50%时应暂时中断治疗并随访至恢复。
  • Mavacamten可持久改善梗阻性HCM患者的血流动力学、生物标志物及症状。

局限性

  • 为开放标签延伸研究,无对照组。
  • 第180周访视完成率仅42.9%,长期数据尚不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects of mavacamten. METHODS: Participants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion. RESULTS: At the latest data cut-off, 211 (91.3%) of the 231 patients originally enrolled in MAVA-LTE still received mavacamten. Median (range) time on study was 166.1 (6.0-228.1) weeks; 185 (80.1%) and 99 (42.9%) patients had completed the Week 156 and 180 visits, respectively. Sustained reductions from baseline to Week 180 occurred in left ventricular outflow tract gradients [mean (standard deviation): resting, -40.3 (32.7) mmHg; Valsalva, -55.3 (33.7) mmHg], N-terminal pro B-type natriuretic peptide [median (interquartile range): -562 (-1162.5, -209) ng/L], and EQ-5D-5L score [mean (standard deviation): 0.09 (0.17)]. Mean left ventricular ejection fraction (LVEF) decreased from 73.9% (baseline) to 66.6% (Week 24) and 63.9% (Week 180). At Week 180, 74 (77.9%) of the 95 patients improved by at least one New York Heart Association class from baseline. Over 739 patient-years exposure, 20 patients (8.7%; exposure-adjusted incidence: 2.77/100 patient-years) experienced 22 transient reductions in LVEF to <50% resulting in temporary treatment interruption (all recovered LVEF of ≥50%). Five (2.2%) patients died (all considered unrelated to mavacamten). CONCLUSIONS: Long-term mavacamten treatment resulted in sustained improvements in cardiac function and symptoms in patients with obstructive HCM, with no new safety concerns identified. Transient, reversible reductions in LVEF were observed in a small proportion of patients during long-term follow-up.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Garcia-Pavia P, Oręziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024. PMID: 39217450. doi:10.1093/eurheartj/ehae579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。